Sponsored Content

MGC Pharmaceuticals (ASX:MXC) has released an announcement that its genetic cannabis strains have received independent verification from the University of Ljubljana in Slovenia.

MXC’s says it has developed two cannabis strains that have a very high concentration of THC (tetrahydrocannabinol) and CBD (cannabidiol).

What are THC and CBD?

 

THC and CBD are two of the hundreds of cannabinoids found in the cannabis plant. They are the two main cannabinoids that are receiving the most medical interest.

THC is said to increase appetite and decrease nausea. It is also expected to decrease pain and inflammation, while CBD is being used in also in the treatment of pain and inflammation and in controlling epileptic seizures.

The company’s MXC-10 strain is reported to contain over 35 percent THC and MXC-81 yields 20 percent CBD and less than one percent THC.

The strains underwent independent laboratory testing at the University’s Biotechnical Faculty and Pharma Lab.

Why is it important to MXC?

 

The significance of such a high cannabis strain is that MXC will yield much higher amounts of the active pharmaceutical ingredients (APIs) from one crop – allowing them to extract cost effective and affordable phytomedicines.

The University has verified that all compliance procedures and protocols were adhered to during the extraction process.

MXC hopes that its operating costs will also be lowered as it will be able to produce high quantities of the extract material for processing into cannabis medicines from smaller crops.

Roby Zomer, Co-founder and Managing Director of MGC Pharmaceuticals elaborated on the importance of its high yielding cannabis strains.

“A higher concentration in the plant of THC and CBD allows us to extract a much higher quantity of the active pharmaceutical ingredient from a smaller crop,” said Zomer.

“We can then scale up production while streamlining operations due to the cost-effective nature of the yield,” he continued.

“We intend to use these strains in our next crops with the intention of further improving the yields we have been achieving.”

This content is produced by Star Investing in commercial partnership with MGC Pharmaceuticals. This content does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.